

Overcoming Disease Recurrence and Treatment Resistance in HER2-Positive Metastatic Tumors – Tweetorial #2 References

Tweet 4

Cortés J, Kim SB, Chung WP, et al. LBA1 Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+ metastatic breast cancer (mBC): Results of the randomized phase III DESTINY-Breast03 study. *Ann Oncol*. 2021;32:S1287-S1288. doi:10.1016/j.annonc.2021.08.2087

Hurvitz S, Kim S-B, Chung W-P, et al. GS3-01 Trastuzumab deruxtecan (T-DXd; DS-8201a) vs. trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (mBC): subgroup analyses from the randomized phase 3 study DESTINY-Breast03. Presented at: SABCS; December 9 2021; San Antonio, Texas.

Tweet 5

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Breast Cancer (v1.2022). Updated November 24, 2021. Accessed December 1, 2021. https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf

Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. *N Engl J Med*. 2012;367(19):1783-91. doi:10.1056/NEJMoa1209124

Tweet 7

Lin NU, Murthy RK, Abramson V, et al. PD4-04 updated results of tucatinib vs placebo added to trastuzumab and capecitabine for patients with previously treated HER2+ metastatic breast cancer with brain metastases (HER2CLIMB). Presented at: SABCS; December 8 2021; San Antonio, Texas.

Murthy RK, Loi S, Okines A, et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. *N Engl J Med*. 2020;382(7):597-609. doi:10.1056/NEJMoa1914609

Tweet 8

ENHERTU® (fam-trastuzumab deruxtecan-nxki) [prescribing information]. Daiichi Sankyo, Inc. Approved 2019. Revised January 2021.

https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761139s011lbl.pdf

KADCYLA® (ado-trastuzumab emtansine) [prescribing information]. Genentech. Approved 2013. Revised September 2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf

MARGENZATM (margetuximab-cmkb) [prescribing information]. MacroGenics, Inc. Approved 2020. Revised December 2020.

https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Breast Cancer (v1.2022). Updated November 24, 2021. Accessed December 1, 2021.

https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf

TUKYSATM (tucatinib) [prescribing information]. Seattle Genetics, Inc. Approved 2020. Revised April 2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213411s000lbl.pdf

Tweet 10

Modi S, Saura C, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. *N Engl J Med*. 2020;382(7):610-621. doi:10.1056/NEJMoa1914510

Tweet 11

André F, Shahidi J, Lee C, Wang K, Krop IE. Abstract OT1-07-04: [Fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) vs investigator's choice of treatment in subjects with HER2-positive, unresectable and/or metastatic breast cancer who previously received T-DM1: A randomized, phase 3 trial (DESTINY-Breast02). *Cancer Research*. 2020;80(4 Supplement):OT1-07-04-OT1-07-04. doi:10.1158/1538-7445.Sabcs19-ot1-07-04

ClinicalTrials.gov. DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]. NCT03523585. Updated January 8, 2021. Accessed November 9, 2021. <https://clinicaltrials.gov/ct2/show/NCT03523585>

Tweet 12

Rugo HS, Im S-A, Cardoso F, et al. PD8-01 Phase 3 SOPHIA Study of Margetuximab + Chemotherapy Versus Trastuzumab + Chemotherapy in Patients With HER2+ Metastatic Breast Cancer

After Prior Anti-HER2 Therapies: Final Overall Survival Analysis. Presented at: SABCS; December 9 2021; San Antonio, Texas.

Rugo HS, Im SA, Cardoso F, et al. Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial. *JAMA Oncol*. 2021;7(4):573-584. doi:10.1001/jamaoncol.2020.7932

Tweet 13

André F, Shahidi J, Lee C, Wang K, Krop IE. Abstract OT1-07-04: [Fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) vs investigator's choice of treatment in subjects with HER2-positive, unresectable and/or metastatic breast cancer who previously received T-DM1: A randomized, phase 3 trial (DESTINY-Breast02). *Cancer Research*. 2020;80(4 Supplement):OT1-07-04-OT1-07-04. doi:10.1158/1538-7445.Sabcs19-ot1-07-04

ClinicalTrials.gov. A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer. NCT03975647. Updated November 9, 2021. Accessed November 9, 2021. <https://clinicaltrials.gov/ct2/show/NCT03975647>

ClinicalTrials.gov. DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]. NCT03523585. Updated January 8, 2021. Accessed November 9, 2021. <https://clinicaltrials.gov/ct2/show/NCT03523585>

Cortés J, Kim SB, Chung WP, et al. LBA1 Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+ metastatic breast cancer (mBC): Results of the randomized phase III DESTINY-Breast03 study. *Ann Oncol*. 2021;32:S1287-S1288. doi:10.1016/j.annonc.2021.08.2087

Hurvitz S, Vahdat L, Harbeck N, et al. Abstract OT-28-01: HER2CLIMB-02: A randomized, double-blind, phase 3 study of tucatinib or placebo with T-DM1 for unresectable locally-advanced or metastatic HER2+ breast cancer. *Cancer Res.* 2021;81(4 Supplement):OT-28-01-OT-28-01. doi:10.1158/1538-7445.Sabcs20-ot-28-01

Tweet 14

ClinicalTrials.gov. A Study of tucatinib vs. placebo in combination with ado-trastuzumab emtansine (T-DM1) for patients with advanced or metastatic HER2+ breast cancer. NCT03975647. Updated November 9, 2021. Accessed November 9, 2021. <https://clinicaltrials.gov/ct2/show/NCT03975647>

Hurvitz S, Vahdat L, Harbeck N, et al. Abstract OT-28-01: HER2CLIMB-02: A randomized, double-blind, phase 3 study of tucatinib or placebo with T-DM1 for unresectable locally-advanced or metastatic HER2+ breast cancer. *Cancer Res.* 2021;81(4 Supplement):OT-28-01-OT-28-01. doi:10.1158/1538-7445.Sabcs20-ot-28-01

Tweet 15

ClinicalTrials.gov. A study of tucatinib plus trastuzumab deruxtecan in HER2+ breast cancer (HER2CLIMB-04). NCT04539938. Updated November 9, 2021. Accessed December 13, 2021. <https://clinicaltrials.gov/ct2/show/NCT04539938>

Hamilton E, Carey L, Ramos J, Chen Y, Krop I. OT1-13-01 HER2CLIMB-04: phase 2 trial of tucatinib + trastuzumab deruxtecan in patients with HER2+ locally advanced or metastatic breast cancer with and without brain metastases. Presented at: SABCS; December 8 2021; San Antonio, Texas.

Tweet 16

ClinicalTrials.gov. T-DM1 and tucatinib compared with T-DM1 alone in preventing relapses in people with high risk HER2-positive breast cancer, the CompassHER2 RD trial. NCT04457596. Updated November 3, 2021. Accessed November 9, 2021. <https://clinicaltrials.gov/ct2/show/NCT04457596>

O'Sullivan CC, Ballman KV, McCall L, et al. Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer. *Future Oncol.* 2021;39(15_suppl):TPS595. doi:10.2217/fon-2021-0753

Tweet 17

ClinicalTrials.gov. SYD985 vs. physician's choice in participants with HER2-positive locally advanced or metastatic breast cancer (TULIP). NCT03262935. Updated November 3, 2021. Accessed November 10, 2021. <https://www.clinicaltrials.gov/ct2/show/NCT03262935>

Glossary

2L, second line
ADC, antibody-drug conjugate
AE, adverse event
ALT, alanine transaminase
AST, aspartate transaminase
BC, breast cancer
CBR, clinical benefit rate
Chemo, chemotherapy
CI, confidence interval
CNS, central nervous system
CVD, cardiovascular disease
DCR, disease control rate
DOR, duration of response
FC, fragment crystallizable
HER2/3, human epidermal growth factor receptor 2/3
HR, hazard ratio
iDFS, invasive disease-free survival
IgG1, immunoglobulin G1
ILD, interstitial lung disease
LV, left ventricular
mBC, metastatic breast cancer
Mets, metastases
mDOR, median duration of response
mPFS, median progression free survival
MOA, mechanism of action
mOS, median overall survival
NCCN, National Comprehensive Cancer Network
NE, not evaluable
NR, not reached
ORR, objective response rate
OS, overall survival
PFS, progression-free survival
PPES, palmar–plantar erythrodysesthesia syndrome
QOL, quality of life
SOC, standard of care
T-DM1, trastuzumab emtansine
T-DXd, trastuzumab deruxtecan
TEAE, treatment-emergent adverse event
Tx, treatment
w/, with